ABBV

MKT CAP:$351B

AbbVie Inc.

Market Cap

$351B

Healthcare·Drug Manufacturers - General·🇺🇸 United States·NYSE

Healthcare·Drug Mfg.·🇺🇸·NYSE

Stock Price

$198.54-$30.77 (-13.42%)

Apr 24, 2026

Company Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to sever...

CEO

Robert A. Michael

IPO Date

Jan 2, 2013

Website

www.abbvie.com

Key Metrics TTM

Revenue

$59.8B

+4.6% YoY

Net Income

$5.4B

EPS (Diluted)

$3.04

Free Cash Flow

$13.2B

Revenue / Share

$33.74

Gross Margin

74.6%

Operating Margin

30.8%

Net Margin

9.0%

FCF Margin

22.1%

P/S

5.9x

P/E

64.9x

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Feb 20, 2026

$61.2B+8.6%EPS $2.37

Q4 2025

Feb 20, 2026

$16.6BEPS $1.02

Q2 2025

Aug 4, 2025

$15.4B+6.6%EPS $0.53

Q1 2025

May 9, 2025

$13.3BEPS $0.72

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 20	$12.9B	$7.9B	$3.3B
Q1 21	$13.0B	$8.8B	$4.1B
Q2 21	$14.0B	$9.4B	$4.4B
Q3 21	$14.3B	$10.0B	$4.3B
Q4 21	$14.9B	$10.6B	$5.1B
Q1 22	$13.5B	$9.5B	$4.7B
Q2 22	$14.6B	$10.4B	$3.3B
Q3 22	$14.8B	$9.8B	$4.6B
Q4 22	$15.1B	$11.0B	$5.5B
Q2 23	$13.9B	$9.6B	$4.5B
Q3 23	$13.9B	$7.4B	$2.3B
Q4 23	$14.3B	$8.6B	$3.2B
Q2 24	$14.5B	$10.3B	$4.0B
Q1 25	$13.3B	$9.3B	$3.7B
Q2 25	$15.4B	$11.1B	$4.9B
Q4 25	$16.6B	$14.0B	$5.8B

Valuation

Quarter	P/S	P/E
Q3 20	3.8x	20.9x
Q1 21	4.2x	23.2x
Q2 21	4.0x	33.9x
Q3 21	3.5x	19.4x
Q4 21	4.3x	20.8x
Q1 22	5.1x	23.0x
Q2 22	4.7x	21.4x
Q3 22	4.2x	18.3x
Q4 22	4.9x	24.2x
Q2 23	4.1x	25.5x
Q3 23	4.5x	25.6x
Q4 23	5.0x	40.2x
Q2 24	5.3x	50.3x
Q1 25	6.6x	70.6x
Q2 25	5.7x	74.5x
Q4 25	6.8x	75.6x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 20	$5.8B	$5.6B
Q1 21	$4.9B	$4.7B
Q2 21	$4.9B	$4.7B
Q3 21	$7.9B	$7.7B
Q4 21	$5.1B	$4.9B
Q1 22	$4.9B	$4.7B
Q2 22	$5.0B	$4.9B
Q3 22	$7.6B	$7.4B
Q4 22	$7.4B	$7.2B
Q2 23	$6.3B	$6.1B
Q3 23	$7.6B	$7.4B
Q4 23	$4.8B	$4.5B
Q2 24	$2.3B	$2.0B
Q1 25	$1.6B	$1.4B
Q2 25	$5.2B	$4.9B
Q4 25	$5.2B	$4.9B

Capital Expenditures

Quarter	CapEx
Q3 20	$217M
Q1 21	$188M
Q2 21	$195M
Q3 21	$217M
Q4 21	$187M
Q1 22	$162M
Q2 22	$143M
Q3 22	$177M
Q4 22	$213M
Q2 23	$178M
Q3 23	$219M
Q4 23	$205M
Q2 24	$241M
Q1 25	$235M
Q2 25	$269M
Q4 25	$329M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 20	+52.2%	+64.6%
Q1 21	+49.5%	+87.6%
Q2 21	+62.0%	+89.8%
Q3 21	+37.6%	+3.8%
Q4 21	+15.4%	+1.7%
Q1 22	+4.1%	-1.0%
Q2 22	+4.5%	+18.6%
Q3 22	+3.3%	+1.7%
Q4 22	+1.6%	-2.0%
Q2 23	+2.4%	+6.0%
Q3 23	-4.5%	+3.2%
Q4 23	-3.4%	+8.8%
Q2 24	-4.4%	+8.8%
Q1 25	-3.8%	+2.8%
Q2 25	+10.7%	-9.6%
Q4 25	+16.2%	-2.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 20	$162M	1.3%
Q1 21	$269M	2.1%
Q2 21	$159M	1.1%
Q3 21	$135M	0.9%
Q4 21	$129M	0.9%
Q1 22	$306M	2.3%
Q2 22	$107M	0.7%
Q3 22	$126M	0.9%
Q4 22	$132M	0.9%
Q2 23	$179M	1.3%
Q3 23	$130M	0.9%
Q4 23	$125M	0.9%
Q2 24	$218M	1.5%
Q1 25	$410M	3.1%
Q2 25	$179M	1.2%
Q4 25	$157M	0.9%

OpEx Breakdown

Quarter	R&D	SG&A
Q3 20	$1.8B	$2.8B
Q1 21	$1.9B	$2.8B
Q2 21	$1.9B	$3.2B
Q3 21	$2.1B	$3.1B
Q4 21	$2.2B	$3.3B
Q1 22	$1.6B	$3.1B
Q2 22	$1.9B	$5.4B
Q3 22	$1.7B	$3.3B
Q4 22	$2.0B	$3.4B
Q2 23	$1.7B	$3.3B
Q3 23	$1.7B	$3.4B
Q4 23	$2.2B	$3.2B
Q2 24	$1.9B	$3.4B
Q1 25	$2.1B	$3.3B
Q2 25	$2.1B	$3.3B
Q4 25	$2.6B	$3.9B

Revenue Segments

Quarter	Alphagan/Combigan	Botox Cosmetic	Botox Therapeutic	Duodopa	H U M I R A	Imbruvica	Juvederm Collection	Linzess/Constella	Lumigan/Ganfort	Mavyret	Other Aesthetics	Other Eye Care	Other Neuroscience	Other Products	Ozurdex	Qulipta	Rinvoq	Restasis	Skyrizi	Ubrelvy	Venclexta	Vraylar
Q2 23	$65M	$685M	$748M	$117M	$4.0B	$907M	$368M	$278M	$119M	$387M	$331M	$215M	$70M	$741M	$119M	$96M	$918M	$99M	$1.9B	$196M	$571M	$658M
Q3 23	$70M	$620M	$748M	$118M	$3.5B	$908M	$321M	$288M	$91M	$370M	$298M	$207M	$61M	$782M	$120M	$132M	$1.1B	$117M	$2.1B	$233M	$590M	$751M
Q4 23	$66M	$718M	$776M	$115M	$3.3B	$903M	$334M	$283M	$92M	$309M	$319M	$181M	$66M	$821M	$118M	$180M	$1.3B	$128M	$2.4B	$234M	$589M	$789M
Q2 24	$49M	$729M	$814M	$113M	$2.8B	$833M	$343M	$221M	$103M	$369M	$318M	$225M	$80M	$810M	$124M	$150M	$1.4B	$32M	$2.7B	$231M	$637M	$774M
Q1 25	$60M	$556M	$866M	$96M	$1.1B	$738M	$231M	$148M	$106M	$306M	$315M	$217M	$59M	$747M	$123M	$193M	$1.7B	—	$3.4B	$240M	$665M	$765M
Q2 25	$36M	$692M	$928M	$97M	$1.2B	$754M	$260M	$258M	$103M	$375M	$327M	$250M	$55M	$603M	$125M	$267M	$2.0B	—	$4.4B	$338M	$691M	$900M

Revenue by Geography

Quarter	Non-US	United States
Q3 20	$3.0B	$9.9B
Q1 21	$3.3B	$9.8B
Q2 21	$3.2B	$10.8B
Q3 21	$3.1B	$11.3B
Q4 21	$3.2B	$11.7B
Q1 22	$3.2B	$10.3B
Q2 22	$3.2B	$11.4B
Q3 22	$3.0B	$11.8B
Q4 22	$2.9B	$12.2B
Q2 23	$3.1B	$10.7B
Q3 23	$3.1B	$10.9B
Q4 23	$3.2B	$11.1B
Q2 24	$3.4B	$11.1B
Q1 25	$10.0B	$3.4B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$6.1B	$1.5B	$7.6B
Q2 22	$8.5B	$1.4B	$10.0B
Q3 22	$11.8B	$47M	$11.9B
Q4 22	$9.2B	$28M	$9.2B
Q1 23	$6.7B	$11M	$6.7B
Q2 23	$8.8B	$7M	$8.8B
Q3 23	$13.3B	$3M	$13.3B
Q4 23	$12.8B	$2M	$12.8B
Q1 24	$18.1B	$2M	$18.1B
Q2 24	$13.1B	$27M	$13.2B
Q3 24	$7.3B	$28M	$7.3B
Q4 24	$5.5B	$31M	$5.6B
Q1 25	$5.2B	$1M	$5.2B
Q2 25	$6.5B	$0	$6.5B
Q3 25	$5.6B	$42M	$5.7B
Q4 25	$5.2B	$28M	$5.3B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 20	1.77B	+7.7%	+19.6%
Q1 21	1.77B	+0.1%	+19.5%
Q2 21	1.78B	+0.1%	+19.7%
Q3 21	1.78B	+0.1%	+7.9%
Q4 21	1.78B	+0.1%	+0.2%
Q1 22	1.78B	0.0%	+0.2%
Q2 22	1.78B	-0.1%	0.0%
Q3 22	1.78B	0.0%	-0.1%
Q4 22	1.78B	+0.1%	0.0%
Q2 23	1.77B	-0.4%	-0.4%
Q3 23	1.77B	0.0%	-0.3%
Q4 23	1.77B	+0.1%	-0.2%
Q2 24	1.77B	-0.1%	-0.4%
Q1 25	1.77B	+0.1%	+0.1%
Q2 25	1.77B	0.0%	+0.1%
Q4 25	1.77B	+0.1%	+0.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 20	$430.1K	30K
Q1 21	$276.8K	47K
Q2 21	$297.0K	47K
Q3 21	$305.1K	47K
Q4 21	$297.7K	50K
Q1 22	$270.8K	50K
Q2 22	$291.7K	50K
Q3 22	$296.2K	50K
Q4 22	$302.4K	50K
Q2 23	$277.3K	50K
Q3 23	$278.5K	50K
Q4 23	$286.0K	50K
Q2 24	$289.2K	50K
Q1 25	$242.6K	55K
Q2 25	$280.4K	55K
Q4 25	$291.5K	57K

Revenue / Employee